Revance Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q2 2014 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Revance Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2014 to Q3 2024.
- Revance Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2024 was -$38M, a 73.1% increase year-over-year.
- Revance Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2024 was -$184M, a 55.4% increase year-over-year.
- Revance Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$324M, a 9.3% increase from 2022.
- Revance Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$357M, a 26.8% decline from 2021.
- Revance Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$281M, a 0.27% increase from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)